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CLINICAL APPROACH TO THE DIAGNOSIS OF DISEASES AND DISORDERS 
IN PETS AND DOMESTIC ANIMALS SOMETIMES MISTAKEN FOR ANTI-
COAGULANT TOXICOSIS 
BENNY J. WOODY, College of Veterinary Medicine Mississippi State University, Drawer V, Mississippi State, Missis-
sippi  39762 
ABSTRACT: To differentiate the causes of bleeding disorders requires a basic understanding of the hemostatic process and 
the proper interpretation of history, physical examination, and laboratory tests. A brief overview of the hemostatic process is 
presented. Tables and flow charts are provided to assist in developing a sound clinical approach to the bleeding patient through 
the proper assessment of history, physical examination findings, and laboratory tests. Categories of inherited and acquired 
bleeding disorders are briefly presented. 
Proc. 15th Vertebrate Pest Conf. (J. E. Borrecco & R. E. Marsh, 
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INTRODUCTION 
Patients with inherited and acquired bleeding disorders 
are commonly encountered in clinical veterinary medicine. 
Over the past 40 years, a variety of disease processes that 
result in bleeding disorders have been described in the vet-
erinary literature. Animals have been found to have most of 
the inherited and acquired bleeding disorders found in hu-
mans (Dodds 1988). Causes of these bleeding disorders can 
be categorized into abnormalities involving the blood vessel, 
the platelet, coagulation factors or the fibrinolytic process 
(Table 1). These abnormalities may occur independently or 
concurrently and clinical signs associated with them are of-
ten very similar. This compartmentalized approach aids in 
understanding the major processes of hemostasis; however, 
one must realize that interrelationships exist between all 
components of the hemostatic process. Clinical and labora-
tory assessment of the bleeding patient requires a basic un-
derstanding of the hemostatic process. 
OVERVIEW OF NORMAL HEMOSTASIS 
Effective hemostasis is accomplished through a se-
quence of integrated functions involving the blood vessels, 
platelets, plasma coagulation factors and the fibrinolytic sys-
tem (Feldman et al. 1986). When the vessel wall integrity of 
a small artery or vein is broken, localized vasoconstriction 
normally occurs. This slows blood flow and facilitates the 
accumulation of platelets. Also, endothelium damage in a 
vessel exposes surfaces that promote platelet adherence, 
platelet aggregation and platelet release reactions. The sub-
stances released from platelets further stimulate platelet ag-
gregation, help to maintain vasoconstriction, and contribute 
to the coagulation process. The initial platelet plug which is 
formed at the site of injury is stabilized and eventually re-
placed with fibrin through the complex system of blood co-
agulation. 
Blood coagulation occurs through a series of step-by-
step biochemical reactions, in which an inactive coagulation 
factor is converted to an active coagulation factor. This ac-
tive factor, in turn, converts another inactive factor to its 
active form. This cycle continues until fibrinogen is con-
verted to fibrin and the fibrin is cross-linked to form a stable 
fibrin clot (Figure 1). The coagulation system can be acti-
vated and proceed by either of two pathways, the intrinsic 
system or the extrinsic system. In vivo, activity through both 
systems is important; however, the concept of two separate 
pathways helps in the evaluation of laboratory tests and in the 
categorization of coagulopathies. 
The extrinsic system is initiated when tissue extracts (i.e., 
tissue thromboplastin) are released from damaged endothelial 
cells and complex with Factor VII. The intrinsic system is 
initiated when substances such as collagen, platelets or endo-
toxin activate Factor XII. Both systems share a final common 
pathway that leads to the formation of a stable fibrin clot. This 
common pathway begins with the activation of Factor X. Acti-
vated Factor X in the presence of calcium and Factor V con-
verts prothrombin (Factor II) to thrombin which in turn 
converts fibrinogen (Factor I) to fibrin. Fibrin is then cross-
linked to form a stable fibrin clot. Eventually, the fibrin clot is 
removed through the process of fibrinolysis. 
CLINICAL ASSESSMENT               
Medical History and Physical Examination 
The first step in the clinical assessment of the bleeding 
patient is the development of a complete medical history. The 
history should contain all of the following: chief complaint, 
signalment (i.e., age, breed, sex), details of present illness, past 
medical or surgical problems, health maintenance (i.e., vacci-
nations, routine diagnostic testing, treatments), previous and 
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Figure 1. Schematic depicting the intrinsic and extrinsic coag-
ulation pathways.
Table 1. Categorization of hemostatic disorders identified in animals. 
(Modified from Lewis and Dhein, 1990). 
present drug history, diet, environment, family history, and a 
general systems review (e.g., coughing, sneezing, vomiting, 
diarrhea, discharges, lameness, appetite, water consumption, 
urination, weight gain or loss, etc.) 
Particular attention should be given to the signalment, 
family history, drug history, and environment (Table 2). The 
signalment and family history can provide valuable informa-
tion to support whether the bleeding disorder is inherited or 
acquired. Inherited disorders tend to become evident early in 
life, usually during the first 6 to 12 months (Troy 1984). A 
history of excessive bleeding associated with minor trauma, 
loss of deciduous teeth, or elective surgical procedures (e.g., 
ear cropping, tail docking, onchyectomy, ovariohysterectomy, 
castration, etc.) is supportive of an inherited hemostatic de-
fect. However, some mild forms of inherited hemostatic de-
fects may not be evident until the animal is an adult (i.e., von 
Willebrand's disease). Information regarding bleeding disor-
ders in close relatives may provide information to support an 
inherited disorder. Since some inherited bleeding disorders 
(i.e., hemophilia A and hemophilia B) are transmitted as re-
cessive sex-linked traits, these disorders are seen primarily in 
the male with the female being an asymptomatic carrier 
(Johnston 1988). Inherited bleeding disorders are more com- 
mon in purebred animals and some inherited bleeding disor-
ders occur with a high frequency within a particular breed, for 
example von Willebrand's disease in doberman pinschers. 
A detailed history of recent or current drug administra-
tion including vaccinations must be obtained. Drugs such as 
aspirin and other non-steroidal anti-inflammatory drugs, and 
some antibiotics interfere with normal platelet function. 
Modified-live virus vaccines can cause a decrease in platelet 
numbers for up to 10 days following vaccination (Johnston 
1989). Although alone, most of these drugs do not cause 
clinical bleeding in a normal animal; however, when admin-
istered to an animal with a pre-existing hemostatic defect 
they may lead to a severe bleeding episode. Review of past 
medical problems and treatments is helpful when attempting 
to determine underlying or concurrent conditions which could 
contribute to the hemostatic compromise. Underlying neo-
plastic diseases, organ failure, infectious agents, and inflam-
matory processes are likely reasons for hemostatic disorders 
to occur in the adult animal (Troy 1984). Environmental his-
tory is important when attempting to ascertain the likelihood 
of exposure to toxic drugs or chemicals such as anticoagulant 
rodenticides. 
A complete physical examination must be performed to 
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Table 2. Historical questions which are essential to ask in the 
work-up of a bleeding patient. 
Table 3. Physical findings and their relationship to the 
hemostatic process. 
 
determine the nature of the hemorrhage. The nature of the 
bleeding may be particularly useful when attempting to deter-
mine if the bleeding episode is primarily due to vascular, 
platelet, or coagulation factor abnormalities (Table 3). In an 
attempt to identify additional diseases or conditions which 
may be causing or contributing to the hemostatic compro-
mise, physical findings in addition to the bleeding (e.g., fever, 
lymphadenomegaly, splenomegaly, hepatomegaly, mental 
status, heart and lung sounds, abdominal distension, joint dis-
tension, lameness, icterus, mucous membrane color, etc.) 
must be noted. These additional physical findings may pro-
vide clues as to the cause of the hemorrhage. 
Laboratory Evaluation 
Although a specific hemostatic abnormality can be sus-
pected from a complete history and physical examination, 
laboratory testing is usually essential in the determination of a 
definitive diagnosis. A minimum data base for the patient 
(e.g., complete blood count, biochemical profile, urinalysis, 
fecal examination, etc.) should be obtained in an attempt to 
identify additional diseases or conditions which may be caus-
ing or contributing to the hemostatic compromise or which 
may affect treatment. Laboratory tests for evaluating the he-
mostatic process can be divided into two categories: screen-
ing tests and specialized tests. The screening laboratory tests 
should be chosen to evaluate all components of the hemo-
static process. Once this is accomplished, more specific test-
ing may be required to obtain a definitive diagnosis. 
The most commonly performed screening tests (Table 4) 
include the platelet count, mucosal bleeding time, activated 
partial thromboplastin time (APTT), activated coagulation 
time (ACT), one-stage prothrombin time (OSPT), thrombin 
clotting time (TT), proteins involved in vitamin K absence or 
antagonism (PIVKA), fibrinogen, and fibrin degradation 
products (FDPs). Each of these screening tests have been 
described in detail in previous publications (Davey 1979, 
Feldman et al. 1986, Johnston 1989, Lewis and Dhein 1990). 
The clinical applications of the screening tests are depicted in 
Figures 2 and 3. 
Results of the clinical evaluation and coagulation screen-
ing tests may dictate that more specific and specialized test-
ing be performed to obtain a definitive diagnosis. Some of the 
specialized tests include specific factor assays for inherited 
factor deficiencies, platelet aggregation for platelet function 
defects, bone marrow evaluation for qualitative platelet disor-
ders, Factor VIII-related antigen for von Willebrand's dis-
ease, toxicological assays for anticoagulant rodenticides, and 
anti-thrombin III levels for the management of DIC. 
CLINICAL DISORDERS 
Vascular Disorders 
Defects in blood vessels may be inherited or acquired. 
Ehlers-Danlos syndrome is the best described inherited vas-
cular disease in which abnormal collagen weakens vessel 
support so that bleeding occurs. Acquired vascular disorder 
may be due to vasculitis. Common causes of vasculitis in-
clude immune-mediated mechanisms, viral infections, and 
rickettsial infections (Troy 1984). Prolonged mucosal bleed-
ing time with the exclusion of thrombocytopenia, platelet 
dysfunction and normal coagulation tests are the most acces-
sible methods for the diagnosis of vascular abnormalities. 
Thrombocytopenia 
Thrombocytopenia may be inherited or acquired; how-
ever, acquired causes of thrombocytopenia are much more 
common in veterinary medicine. Thrombocytopenia is due to 
decreased production, increased usage, increased destruction, 
or sequestration of the platelets (Table 1). Spontaneous hem-
orrhage rarely occurs until the platelet count is less than 
50,000 per microliter (normal platelet count, greater than 
200,000 per microliter). Hemorrhage occurring in patients 
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Table 4. Screening laboratory tests used to evaluate the hemostatic process. 
 
 
 
Figure 2. An algorithm for the clinical approach to the patient 
with abnormal hemostasis and a decreased platelet count (modi-
fied from Troy, 1984). 
 
with platelet counts greater than 50,000 per microliter is in-
dicative of concurrent vessel abnormalities, platelet function 
abnormalities, or coagulopathy. 
Bone marrow evaluation is indicated in thrombo-
cytopenic animals. Increased numbers of megakaryocytes in 
the bone marrow is suggestive of diseases causing either in-
creased usage or destruction of the circulating platelet. 
Whereas, decreased numbers of megakaryocytes in the 
bone marrow is suggestive of disease processes leading to 
decreased production. 
Thrombocytopathia 
Thrombocytopathia or qualitative platelet defects may 
be inherited or acquired. These defects in platelet function 
may cause abnormalities in platelet adhesion, aggregation, 
and release reactions. 
Von Willebrand's disease is the most frequently reported 
inherited thrombocytopathia characterized by decreased 
platelet adhesiveness. Von Willebrand's disease is inherited 
as an autosomal recessive or as an autosomal incomplete 
dominant trait (Troy 1984). In most cases of von Willebrand's 
disease, spontaneous bleeding is not clinically evident. 
Bleeding disorders are recognized when an animal undergoes 
surgery or sustains trauma. However, coexisting disease pro-
cesses such as hypothyroidism, uremia, liver disease, drug 
administration, or infections may cause severe bleeding. Von 
Willebrand's disease has been diagnosed in a large number of 
dog breeds and occasionally in cats, pigs and horses. A high 
incidence of von Willebrand's disease has been reported in 
the following breeds of dogs: doberman pinscher, Shetland 
sheepdog, golden retriever, German shepherd, Scottish ter-
rier, miniature schnauzer, Welsh Pembroke corgi, Manchester 
terrier and basset hound. Von Willebrand's disease should be 
suspected in patients with prolonged mucosal bleeding time 
with normal platelet counts and coagulation tests. Specific 
diagnosis is based on Factor VIII-related antigen assay. 
Defects in platelet aggregation is seen as an inherited 
disorder in the otterhound (thrombasthenia) and in the fox 
hound, basset hound and cats (thrombopathia). Defects of 
acquired platelet aggregation is most often secondary to drug 
administration (especially non-steroidal anti-inflammatory 
drugs) or due to gammopathies. 
Figure 3. An algorithm for the clinical approach to the patient 
with abnormal heomstasis and a normal platelet count (modi-
fied from Troy, 1984). 
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Hereditary Coagulopathies 
Hereditary coagulopathies are less common than ac-
quired coagulopathies. They are generally due to a single 
factor deficiency. Regardless of the type of coagulopathy, 
clinical signs are similar. Table 5 provides a listing of re-
ported hereditary coagulopathies and the species affected 
(Feldman 1986). 
Acquired Coagulopathies 
Clinically, acquired coagulopathies can generally be 
viewed as either vitamin K antagonism/deficiency, liver dis-
ease, or disseminated intravascular coagulopathy (DIC). 
Vitamin K is required for carboxylation of glutamic acid 
residues in Factors II, VII, IX and X. When these coagulation 
factors are produced in the absence of vitamin K they are 
inactive. Since Factor VII (extrinsic system) has the shortest 
half-life (4 to 6 hours) of the vitamin K-dependent coagula-
tion factors, prolongation of the OSPT is recognized prior to 
prolongation of the APTT or ACT (Feldman 1981). The 
PIVKA test detects non-functional precursors of the vitamin 
K-dependent coagulation factors. The PIVKA test will be-
come positive 12 to 24 hours prior to prolongation of the 
OSPT (Lewis and Dhein 1990). 
Animals require a continuous supply of vitamin K since 
storage of vitamin K is limited to only a few days. Vitamin K 
is found in vegetable oils and leafy plants and it is synthe-
sized by gastrointestinal bacteria. Vitamin K is fat soluble 
and bile acids are required to emulsify fats to facilitate its 
absorption from the gastrointestinal tract. Vitamin K defi-
ciency may develop due to gastrointestinal disorders (i.e., fat 
malabsorption, complete bile duct obstruction, pancreatic 
exocrine insufficiency and gastrointestinal tract sterilization 
with antibiotics) (Feldman 1981, Feldman 1986). Even 
though vitamin K deficiency has been reported in animals, 
vitamin K antagonism secondary to anticoagulant rodenti-
cides ingestion is much more common. 
Liver Disease 
Bleeding disorders associated with liver disease are of-
ten multifactorial. All coagulation factors except for Factor 
VIII are produced by the liver. Patients with liver disease are 
often thrombocytopenic. This is partially due to platelet se-
questration associated with portal hypertension and splenic 
enlargement. Patients with liver disease may also develop 
DIC leading to thrombocytopenia, coagulation factor defi-
ciencies, and increased FDPs. The liver normally aids in the 
removal of FDPs from circulation. In liver disease, FDPs 
accumulate and lead to further defects in coagulation. Pa-
tients with chronic liver disease may also synthesize an ab-
normal fibrinogen which interferes with the formation of a 
stable fibrin clot (Feldman 1981). 
Disseminated Intravascular Coagulopathy 
Disseminated intravascular coagulopathy commonly oc-
curs secondary to a wide variety of clinical conditions. Any 
disease which produces vascular stasis or breakdown of vas-
cular endothelium favors the induction of DIC. Activation of 
the coagulation system leads to uncontrolled microvascular 
thrombosis. Bleeding tendencies develop as coagulation fac-
tors and platelets are consumed and these bleeding tendencies 
are potentiated as FDPs accumulate due to uncontrolled fi-
brinolysis. Diagnosis of DIC is supported by thrombo-
cytopenia, prolongation of APTT, ACT and OSPT, and 
elevations of FDPs. Since DIC is always secondary to an-
other disease process, treatment, where possible, must be di-
rected at the underlying cause. 
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